Chemosensitization of solid tumors by modulation of resistance mechanisms

Current Opinion in Investigational Drugs

Volumn 3, Issue 4, 2002, Pages 634-640

  Cree, Ian A ^a   Knight, Louise ^a   Di Nicolantonio, Federica ^a   Sharma, Sanjay ^a   Gulliford, Tim ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Chemosensitization; Chemotherapy; DNA repair; Resistance; Synergy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ANTHRACYCLINE; BIRICODAR; BUTHIONINE SULFOXIMINE; CYCLOSPORIN; CYTIDINE DERIVATIVE; DNA; DNA POLYMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELACRIDAR; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GLUTATHIONE; GLYCOPROTEIN P; METALLOTHIONEIN; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN INHIBITOR; PLATINUM; PROTEIN INHIBITOR; SALAZOSULFAPYRIDINE; TARIQUIDAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINCRISTINE; ZOSUQUIDAR; ANTINEOPLASTIC AGENT; XENOBIOTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL POPULATION; CHEMOSENSITIVITY; CLINICAL TRIAL; DETOXIFICATION; DNA DAMAGE; DNA REPAIR; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOXICITY; EXCISION REPAIR; FEASIBILITY STUDY; HUMAN; ION TRANSPORT; MOLECULE; REVIEW; SOLID TUMOR; TUMOR CELL; XENOBIOTIC METABOLISM; DRUG DETOXIFICATION; DRUG INTERACTION; DRUG RESISTANCE; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; DNA REPAIR; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; HUMAN; METABOLIC DETOXICATION, DRUG; NEOPLASMS; P-GLYCOPROTEIN; SUPPORT, NON-U.S. GOV'T; XENOBIOTICS; HUMANS;

EID: 0036528363     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity
2. Correlation of drug resistance associated parameters in ovarian tumor biopsies
3. Resistance to cisplatin
4. P-glycoprotein and bioavailability-implication of polymorphism
5. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts
6. Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines
7. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1
8. Resistance circumvention strategies tested in clinical leukaemia specimens using the MTT colorimetric assay
9. Chemosensitisation by verapamil and cyclosporin A in mouse tumor cells expressing different levels of P-glycoprotein and CP22 (sorcin)
10. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR)
11. BIRICODAR (VX-710; Incel): An effective chemosensitizer in neuroblastoma
12. Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro
13. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily
14. Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma
15. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia
16. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
17. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6α-hydroxypaclitaxel, a major metabolite of paclitaxel
18. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576
19. Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: High-dose oral tamoxifen and dexverapamil
20. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin
21. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration
22. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
23. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin
24. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
25. French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumors. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumors. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris
26. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer
27. The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11
28. Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation
29. Resistance circumvention strategies tested in clinical leukaemia specimens using the MTT colorimetric assay
30. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumor growth of B16 melanoma
31. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan
32. Modulation of cisplatin cytotoxicity by sulphasalazine
33. Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine
34. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity
35. Enhanced expression of metallothionein in human non-small-cell lung carcinomas following chemotherapy
36. Expression of metallothionein in colorectal cancers and synchronous liver metastases
37. Metallothionein expression in patients with small cell carcinoma of the lung: Correlation with other molecular markers and clinical outcome
38. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells
39. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis
40. Metallothionein and anticancer agents: The role of metallothionein in cancer chemotherapy
41. Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines
42. DNA alkylation and interstrand cross-linking by treosulfan
43. Modulation of 1,3-bis-(2-chloroethyl)-1-nitrosourea resistance in human tumor cells using hammerhead ribozymes designed to degrade O6-methylguanine DNA methyltransferase mRNA
44. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma
45. 6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts
46. 6-methylguanine-DNA methyltransferase (MGMT): Synthesis, molecular modeling, and structure-activity relationships
47. Resistance to topoisomerase poisons due to loss of DNA mismatch repair
48. Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts
49. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells
50. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses
51. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
52. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival
53. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy
54. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy
55. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents
56. Interaction between cisplatin and gemcitabine in vitro and in vivo
57. Synergistic interaction between cisplatin and gemcitabine in vitro
58. Preclinical combination therapy with gemcitabine and mechanisms of resistance
59. Basis for effective combination cancer chemotherapy with antimetabolites
60. Combination chemotherapy for chroroidal melanoma: Ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside
61. Cell cycle and melanoma - Two tumors from the same cell type
62. TCA-100 tumor chemosensitivity assay: Differences in sensitivity between cultured tumor cell lines and clinical studies
63. ATP-based tumor chemosensitivity testing: Assisting new agent development
64. Phagocyte chemiluminescence
65. Genome maintenance mechanisms for preventing cancer
66. Unraveling DNA repair in human: Molecular mechanisms and consequences of repair defect